CORONA Remedies Limited (NSE:CORONA)
2,098.20
-14.80 (-0.70%)
At close: Jul 27, 2026
CORONA Remedies Ratios and Metrics
Market cap in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Total Valuation
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 24, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
| 128,326 | 95,165 | - | - | - | - | |
Market Cap Growth | - | - | - | - | - | - |
Enterprise Value | 129,686 | 95,253 | - | - | - | - |
Last Close Price | 2098.20 | 1547.53 | - | - | - | - |
Price Ratios
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 24, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
PE Ratio | 69.32 | 51.41 | - | - | - | - |
Forward PE | 51.33 | 40.71 | - | - | - | - |
PS Ratio | 9.15 | 6.78 | - | - | - | - |
PB Ratio | 17.18 | 12.74 | - | - | - | - |
P/TBV Ratio | 26.51 | 19.66 | - | - | - | - |
P/FCF Ratio | 231.84 | 171.93 | - | - | - | - |
P/OCF Ratio | 55.92 | 41.47 | - | - | - | - |
PEG Ratio | 1.97 | 1.61 | - | - | - | - |
EV Ratios
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 24, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
EV/Sales Ratio | 9.24 | 6.79 | - | - | - | - |
EV/EBITDA Ratio | 44.11 | 32.82 | - | - | - | - |
EV/EBIT Ratio | 50.58 | 37.19 | - | - | - | - |
EV/FCF Ratio | 234.30 | 172.09 | - | - | - | - |
Financial Efficiency
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 24, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Debt / Equity Ratio | 0.22 | 0.22 | 0.14 | 0.33 | 0.07 | 0.14 |
Debt / EBITDA Ratio | 0.56 | 0.56 | 0.36 | 1.02 | 0.22 | 2.62 |
Debt / FCF Ratio | 2.98 | 2.98 | 0.87 | - | 3.52 | 0.73 |
Net Debt / Equity Ratio | 0.18 | 0.18 | 0.03 | 0.32 | 0.02 | 0.10 |
Net Debt / EBITDA Ratio | 0.47 | 0.47 | 0.08 | 1.01 | 0.06 | 2.10 |
Net Debt / FCF Ratio | 2.46 | 2.46 | 0.18 | -1.19 | 0.94 | 0.51 |
Asset Turnover | 1.31 | 1.31 | 1.36 | 1.42 | 1.60 | 1.18 |
Inventory Turnover | 2.14 | 2.14 | 2.13 | 2.29 | 2.40 | 2.86 |
Quick Ratio | 0.49 | 0.49 | 0.79 | 0.47 | 0.78 | 0.60 |
Current Ratio | 0.96 | 0.96 | 1.41 | 1.29 | 2.12 | 1.92 |
Return on Equity (ROE) | 27.36% | 27.36% | 27.50% | 20.36% | 23.29% | -0.12% |
Return on Assets (ROA) | 14.99% | 14.99% | 14.45% | 11.21% | 12.19% | -0.31% |
Return on Invested Capital (ROIC) | 25.42% | 26.16% | 24.33% | 18.58% | 21.48% | -0.76% |
Return on Capital Employed (ROCE) | 30.30% | 30.30% | 29.50% | 21.10% | 23.60% | -0.70% |
Yields
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 24, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Earnings Yield | 1.44% | 1.94% | - | - | - | - |
FCF Yield | 0.43% | 0.58% | - | - | - | - |
Dividend Yield | 0.47% | 0.65% | - | - | - | - |
Payout Ratio | 24.15% | 24.15% | 15.14% | 18.72% | 8.21% | - |
Buyback Yield / Dilution | - | - | - | -4.89% | -14.21% | 16.53% |
Total Shareholder Return | 0.47% | 0.65% | - | -4.89% | -14.21% | 16.53% |